BioNTech SE share price logo

BioNTech SE

NASDAQ: BNTX

$111.37

-1.19

(-1.06%)

as on

BioNTech SE Stock Performance

as on August 28, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $110.25
    $112.81
    downward going graph

    1.01%

    Downside

    1.29%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $79.52
    $124.00
    downward going graph

    28.60%

    Downside

    11.34%

    Upside

    downward going graph

BioNTech SE share price movements today

Previous Close
$112.56
Open
$111.90
Volume
1.3M
Market Cap
$28.3B
Day's Low - High
$110.25 - $112.81
52 Week Low - High
$79.52 - $124.00

BioNTech SE Historical Returns

1 Month Return
+ 23.57 %
3 Month Return
+ 21.03 %
1 Year Return
+ 9.27 %
3 Year Return
-4.29 %
5 Year Return
-68.6 %

BioNTech SE Stock Fundamentals & Key Indicators

Check BioNTech SE market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$28.3B

EPS (TTM)

-4.9657

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.43%

PE Ratio (TTM)

0

PEG Ratio

0.046

EBITDA

-1.4B

Revenue (TTM)

2.6B

Profit Margin

-63.64%

Return On Equity TTM

-9.30%

BioNTech SE vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of BioNTech SE with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$28.3B-68.6%NA-63.64%NA
BUY$45.3B655.66%NA0.00%NA
BUY$140.1B173.75%31.9286.04%NA
BUY$63.4B-60.84%-7.98-12.57%NA
BUY$85.3B22.84%19.984.86%0.44%

Stock Returns calculator for BioNTech SE Stock including INR - Dollar returns

The BioNTech SE stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

BioNTech SE investment value today

Current value as on today

₹1,17,821

Returns

₹17,821

(+17.82%)

Returns from BioNTech SE Stock

₹8,116 (+8.12%)

Dollar Impact

₹9,705 (+9.71%)

Analyst Recommendation on BioNTech SE Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33333333333334% of analysts recommend a 'BUY' rating for BioNTech SE. Average target price of $121.37

BioNTech SE Share Price Target

Get share price movements and forecasts by analysts on BioNTech SE.

What analysts predicted

8.24%UPSIDE

Target Price

$121.37

Current Price

$111.37

Analyzed by

12 Analysts

Target

$121.37

BioNTech SE target price $121.37, a slight upside of 8.24% compared to current price of $111.37. According to 12 analysts rating.

Indian Investors' Interest in BioNTech SE Stock

Search interest for BioNTech SE Stock has increased by 78% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:78% versus previous 30 day period

BioNTech SE Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
203
138
1,382
1,245
197
260
1,518
898
120
105
Gross Profit
139
74
1,183
990
107
184
1,370
568
-75
8
Operating Income
-507
-966
10
148
-534
-501
-46
-230
-671
-948
EBITDA
-288
-752
211
464
-368
-348
149
-55
-450
-584
Interest Expense
4
7
5
7
6
3
0
6
4
7
Depreciation
38
49
44
165
42
51
124
164
121
266
Income Before Tax
-331
-805
158
301
-445
-402
24
-225
-577
-858
Income Tax Expense
-16
2
-39
41
-29
-16
53
76
-36
-37
Net Income
-342
-869
219
271
-449
-386
-28
-302
-540
-820
Net Profit Margin
-167.96%
-627.66%
15.91%
21.81%
-227.46%
-148.24%
-1.89%
-33.61%
-450.38%
-777.27%

BioNTech SE Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
72
145
120
586
21,452
18,318
4,166
2,878
2,756
Gross Profit
61
129
101
514
18,161
15,149
3,511
2,311
2,140
Operating Income
-61
-53
-181
-82
15,283
12,642
690
-1,314
-623
EBITDA
-74
-23
-143
-105
15,002
13,096
1,377
-367
-627
Interest Expense
0
1
1
1
5
15
7
13
13
Depreciation
10
21
33
38
75
123
183
298
382
Income Before Tax
-85
-47
-179
-145
15,046
12,954
1,186
-677
-1,009
Income Tax Expense
0
0
0
-161
4,753
3,519
255
-12
81
Net Income
-101
-54
-199
18
11,635
9,983
1,014
-696
-1,091
Net Profit Margin
-139.05%
-37.64%
-164.92%
3.15%
54.24%
54.50%
24.36%
-24.18%
-39.59%

BioNTech SE Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-869
217
276
-437
-438
-33
-302
-540
-834
Operating Cash Flow
1,759
-687
-501
-821
132
854
299
-427
10
Investing Cash Flow
-248
-162
649
1,312
-26
-995
-2,626
2,694
-103
Financing Cash Flow
-24
-8
-8
-14
-14
-14
-13
26
-110
Change in Cash
1,426
-379
-633
893
1,053
-195
-2,421
2,117
-275

BioNTech SE Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-47
-179
-145
15,046
12,954
1,186
-677
-1,091
Operating Cash Flow
-58
-198
-13
889
13,577
5,371
207
438
Investing Cash Flow
-67
-77
-144
-566
-35
-6,954
-2,081
-2,371
Financing Cash Flow
365
383
894
94
-1,419
-778
-45
-50
Change in Cash
239
107
691
482
12,182
-2,211
-1,901
-931

Mutual Funds that own BioNTech SE Stock

Check out the Mutual Funds with significant holdings in BioNTech SE.

Funds
Holdings
Shares Held
Dodge & Cox Funds
1.211559%
3043491
Fidelity Contrafund
0.989018%
2484457
T. ROWE PRICE CAPITAL APPRECIATION FUND, INC.
0.904616%
2272437
VANGUARD HORIZON FUNDS
0.871449%
2189120
PRIMECAP Odyssey Funds
0.507453%
1274746

Global Institutional Holdings in BioNTech SE

Funds
Holdings
Theofanis Kolokotrones
1.5%
John A. Gunn
1.46%
iShares
0.4%
First Trust
0.39%
Schwab
0.11%

BioNTech SE News & Key Events

  • img

    Today's Timeline - 03 August

    Mon, 04:24 PM

    -

    BioNTech appoints Guido Oelkers as CEO, effective by February 1, 2027, succeeding Ugur Sahin.

Insights on BioNTech SE

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, BNTX stock has moved up by 23.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 33.7% return, outperforming this stock by 38.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 496.3% return, outperforming this stock by 487.0%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 1.51B → 105.6M (in $), with an average decrease of 46.5% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, -28.70M → -820.79M (in $), with an average decrease of 361.2% per quarter

About BioNTech SE

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
OrganisationBioNTech SE
HeadquartersAn der Goldgrube 12, Mainz, Germany, 55131
IndustryBiotechnology
CEODr. Ugur Sahin M.D.
E-voting on sharesClick here to vote

Key Management of BioNTech SE

Name

Title

Mr. Ramon Zapata-Gomez

CFO & Member of Management Board

Dr. Sierk Pötting Ph.D.

MD, COO & Member of Management Board

Dr. James Timothy Patrick Ryan Ph.D.

Chief Legal & Business Officer and Member of the Management Board

Ms. Annemarie Hanekamp

Chief Commercial Officer & Member of Management Board

Mr. Douglas Maffei Ph.D.

Vice President of Strategy & Investor Relations

Dr. Ugur Sahin M.D.

Co-Founder, CEO & Chair of the Management Board

Dr. Ozlem Tureci M.D.

Co-Founder, Chief Medical Officer & Member of Management Board

Ms. Kylie Jimenez

Chief People Officer & Member of Management Board

Ms. Lisa Birringer

Senior Vice President of Global Financial Reporting & Accounting

Jasmina Alatovic

Vice President Corporate Communications

FAQs

What is BioNTech SE share price today?

BioNTech SE share price today is $111.37 as on at the close of the market. BioNTech SE share today touched a day high of $112.81 and a low of $110.25.

What is the 52 week high and 52 week low for BioNTech SE share?

BioNTech SE share touched a 52 week high of $124.00 on and a 52 week low of $79.52 on . BioNTech SE stock price today i.e. is closed at $111.37,which is 10.19% down from its 52 week high and 40.05% up from its 52 week low.

What is BioNTech SE's market capitalisation today?

BioNTech SE market capitalisation is $0.03T as on .

How to invest in BioNTech SE Stock (BNTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for BioNTech SE on INDmoney app. Click on Buy button. You can invest as low as $1.5 in BioNTech SE Shares that will get you 0.0135 shares as per BioNTech SE share price of $111.37 per share as on August 28, 2026 at 1:29 am IST.

What is the minimum amount required to buy BioNTech SE Stock (BNTX) from India?

Indian investors can start investing in BioNTech SE (BNTX) shares with as little as ₹95.53 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.30 in BioNTech SE stock (as per the Rupee-Dollar exchange rate as on ). Based on BioNTech SE share’s latest price of $111.37 as on August 28, 2026 at 1:29 am IST, you will get 0.0898 shares of BioNTech SE. Learn more about fractional shares .

What are the returns that BioNTech SE has given to Indian investors in the last 5 years?

BioNTech SE stock has given -68.6% share price returns and 30.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?